Lobe Sciences (LOBEF)
OTHER OTC:LOBEF
LOBEF Stock Chart & Stats
$0.04
>-$0.01(-17.06%)
At close: 4:00 PM EST
$0.04
>-$0.01(-17.06%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume171.00
Average Volume (3M)103.94K
Market Cap
$18.46M
Enterprise Value$19.53M
Total Cash (Recent Filing)$4.96M
Total Debt (Recent Filing)$316.49K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,102,500
10 Day Avg. Volume62,263
30 Day Avg. Volume103,939
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Balance-sheet LeverageModest reported debt (debt-to-equity ~0.19, total debt ~$0.3M) reduces immediate solvency pressure and lowers near-term financing constraints. This gives management more flexibility to fund R&D or trials before needing dilutive capital, a durable buffer versus highly leveraged peers.
Demonstrated Gross-profit When Revenue ExistedHistorical periods with revenue produced meaningful gross profit, suggesting the core cost structure can support positive product-level margins. If commercial or clinical-stage milestones convert to recurring revenue, the company has structural potential to scale gross margins before fixed-cost absorption.
Focused Therapeutic Specialization In PsychedelicsA clear strategic focus on psychedelic-derived therapeutics and neurological disorders builds domain expertise and IP potential. Specialization supports differentiated R&D capabilities, long-term partnership appeal, and a targeted market position versus generalist biotechs, aiding durable competitive advantage.
Bears Say
No Revenue And Sizable Operating LossesThe absence of TTM revenue combined with multi-million-dollar operating and net losses shows the business is not yet commercial. Persistent losses constrain the company's ability to self-fund development, extend the cash runway, and increase dependence on external financing over the medium term.
Deeply Negative Operating And Free Cash FlowSustained negative operating and free cash flow (~-$3.4M TTM) indicates recurring cash burn tied to R&D and operations. This persistent outflow raises refinancing risk, can force dilutive capital raises, and limits ability to invest opportunistically in trials or partnerships without external funding.
Historically Unstable Equity And Volatile AssetsPeriods of negative equity and materially swinging total assets signal a fragile capital base and higher financing risk. Unstable equity can restrict access to non-dilutive capital, raise covenant or counterparty concerns, and increase the likelihood of recapitalization or dilution as a structural constraint.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $18.46M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.095%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Ownership Overview
Options Prices
Currently, No data available
---